Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response.
Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A, Taxonera C, Casis B, Tabernero S, Bermejo F, Martinez-Silva F, Mendoza JL, Martinez-Montiel P, Carneros JA, Sanchez F, Maté J, Gisbert JP; Group for the Study of Inflammatory Bowel Diseases from Madrid. Gonzalez-Lama Y, et al. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1609-14. Hepatogastroenterology. 2008. PMID: 19102352
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.
González-Lama Y, López-San Román A, Marín-Jiménez I, Casis B, Vera I, Bermejo F, Pérez-Calle JL, Taxonera C, Martínez-Silva F, Menchén L, Martínez-Montiel P, Calvo M, Carneros JA, López P, Mendoza JL, Milicua JM, Huerta A, Sánchez F, Abreu L, López-Palacios N, Maté J, Gisbert JP; Group for the Study of Inflammatory Bowel Diseases from Madrid (ENICMAD). González-Lama Y, et al. Gastroenterol Hepatol. 2008 Aug-Sep;31(7):421-6. doi: 10.1157/13125587. Gastroenterol Hepatol. 2008. PMID: 18783686
Predictors of response to infliximab in patients with fistulizing Crohn's disease.
Luna-Chadid M, Pérez Calle JL, Mendoza JL, Vera MI, Bermejo AF, Sánchez F, López San Román A, Froilán C, González-Lara V, García-Paredes J, Fernández-Blanco I, Abreu L, Casis B, Solís Herruzo JA, Gisbert JP, Maté Jiménez J. Luna-Chadid M, et al. Rev Esp Enferm Dig. 2004 Jun;96(6):379-81; 382-4. doi: 10.4321/s1130-01082004000600003. Rev Esp Enferm Dig. 2004. PMID: 15230667 Free article. English, Spanish.
Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience.
González-Lama Y, Taxonera C, López-Sanromán A, Pérez-Calle JL, Bermejo F, Pajares R, McNicholl AG, Opio V, Mendoza JL, López P, Algaba A, Estelles J, Barbero A, Mendoza J, Maté J, Gisbert JP; Madrid Group for Study of Inflammatory Bowel Diseases (ENICMAD). González-Lama Y, et al. Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1086-91. doi: 10.1097/MEG.0b013e3283556db5. Eur J Gastroenterol Hepatol. 2012. PMID: 22713509
Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease.
Taxonera C, Rodrigo L, Casellas F, Calvet X, Gómez-Camacho F, Ginard D, Castro M, Castro L, Ponce M, Martínez-Montiel P, Ricart E, Gisbert JP, López-San Román A, Morales JM, Casado MA. Taxonera C, et al. J Clin Gastroenterol. 2009 Nov-Dec;43(10):950-6. doi: 10.1097/MCG.0b013e3181986917. J Clin Gastroenterol. 2009. PMID: 19448569
196 results